These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9130607)

  • 21. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capillary zone electrophoresis investigation of the interaction between heparin and granulocyte-colony stimulating factor.
    Liang A; He X; Du Y; Wang K; Fung Y; Lin B
    Electrophoresis; 2004 Mar; 25(6):870-5. PubMed ID: 15004848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin).
    Vijayabaskar P; Balasubramanian T; Somasundaram ST
    Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):175-80. PubMed ID: 18597000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin binding and augmentation of C1 inhibitor activity.
    Caldwell EE; Andreasen AM; Blietz MA; Serrahn JN; VanderNoot V; Park Y; Yu G; Linhardt RJ; Weiler JM
    Arch Biochem Biophys; 1999 Jan; 361(2):215-22. PubMed ID: 9882449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hydrolysis of heparin by the immobilized enzymatic complex from Streptomyces kurssanovii].
    Bannikova GE; Stolbushkina PP; Drozd NN; Vikhoreva GA; Varlamov VP; Makarov VA; Panov AV
    Prikl Biokhim Mikrobiol; 2004; 40(4):429-34. PubMed ID: 15455715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydrolysis of a synthetic amide substrate by human C1 esterase (C1s).
    Morgan PH; Nair IG
    J Immunol; 1977 Jul; 119(1):19-25. PubMed ID: 17638
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of Arg46 and Arg47 of antithrombin in heparin binding.
    Arocas V; Bock SC; Olson ST; Björk I
    Biochemistry; 1999 Aug; 38(31):10196-204. PubMed ID: 10433728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases.
    Ofosu FA
    Thromb Res; 2008; 123(1):5-7. PubMed ID: 18284938
    [No Abstract]   [Full Text] [Related]  

  • 32. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement.
    Ziccardi RJ
    J Immunol; 1982 Jun; 128(6):2505-8. PubMed ID: 7077078
    [No Abstract]   [Full Text] [Related]  

  • 34. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on haemocompatibility.
    Koromila G; Michanetzis GP; Missirlis YF; Antimisiaris SG
    Biomaterials; 2006 Apr; 27(12):2525-33. PubMed ID: 16410022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links.
    Mousa SA
    Semin Thromb Hemost; 2007 Jul; 33(5):524-33. PubMed ID: 17629850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes.
    Ramamurthy N; Baliga N; Wakefield TW; Andrews PC; Yang VC; Meyerhoff ME
    Anal Biochem; 1999 Jan; 266(1):116-24. PubMed ID: 9887220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.